UK markets closed
NIKKEI 225
38,385.73 +29.67 (+0.08%) HANG SENG
19,073.71 -41.35 (-0.22%) CRUDE OIL
78.84 +0.82 (+1.05%) GOLD FUTURES
2,391.30 +31.40 (+1.33%) DOW
39,873.19 +315.08 (+0.80%) Bitcoin GBP
52,104.47 +3,530.72 (+7.27%)
Merck & Co., Inc. (0QAH.IL)
IOB - IOB Delayed price. Currency in USD
Add to watchlist
At close: 07:13PM BST
| Previous close | 128.30 |
| Open | 129.19 |
| Bid | 127.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 128.57 - 131.52 |
| 52-week range | 99.15 - 133.08 |
| Volume | |
| Avg. volume | 192,813 |
| Market cap | 330.893B |
| Beta (5Y monthly) | 0.38 |
| PE ratio (TTM) | 106.89 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.92 (2.83%) |
| Ex-dividend date | 14 Sept 2023 |
| 1y target est | N/A |
- Business Wire
Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
RAHWAY, N.J., May 15, 2024--Merck to Present New Data at 2024 ASCO Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
- Business Wire
Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
RAHWAY, N.J., May 13, 2024--Merck Update on KeyVibe-010 Evaluating Coform of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients W/ Resected High-Risk Melanoma
- Business Wire
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
RAHWAY, N.J., May 09, 2024--Merck Provides Update on Phase 3 KEYNOTE-B21 Trial
© 2024 Yahoo. All rights reserved.